English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Transfusion therapy is the main treatment for patients with trauma, severe hemoglobinopathies and cancer patients. Transfusion of blood products has its own risks causing immediate and delayed adverse reactions. Complications such as transfusion transmitted infectious diseases (TTIDs), antibody formation to red and white cells, and preformed cytokines result in immediate and delayed adverse reactions and health consequences to transfusion recipients. Delayed adverse reactions develop days, months or years after administration of blood and blood products. There have been many advances in technologies and transfusion strategies to decrease the risk of transfusion reactions, yet transfusion services continue to pursue massive efforts to prevent infectious and non-infectious complications associated with blood transfusion. A large number of safety changes have been implemented to improve blood safety. Recently, a large attention has been focused by Transfusion Medicine community to decrease TTIDs for HIV/HBV/ HCV through extensive donor questionnaires, infectious disease testing and introduction of Nucleic Acid testing (NAT) resulting in success in reducing risks of TTIDs.

Prevention of adverse reactions: Journey from blood safety to transfusion safety